LGGs are characterized by mutations in the IDH1 enzyme that decrease tumor aggressiveness by indirectly inhibiting the E2F transcription program, an important switch controlling homeostasis and tumorigenesis [16–18]. This evidence concerns the gene IDH1 and neoplasm.